Epstein Secrets

izer-s-covid-vaccine-trial-plan-may-beat- rivals-to-early-look?smd=premium> (9/22, Langreth, 4.73M) reports, "The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals." The firms "plan a first look

, 716K), and Breitbart <https://vvww.breitbart.corn/politics/2020/09/22/mitt-romney-supports-senate-vote-on-president-trumps-scotus- nominee> (9/22, Bleau, 673K), among other conservative news outlets, running similar analyses. To the New York Times <https://www.nytimestotn/2020/09/22/us/politics/ruth-

n people." Pfizer's COVID Vaccine Trial On Track To Beat Rivals. Bloomberg (9/22, Langreth, 4.73M) reports, "The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals." The firms "plan a first loo

- controlled Senate has enough votes to confirm," with Townhall (9/22, McCarthy, 177K), the Daily Caller (9/22, Rodgers, 716K), and Breitbart (9/22, Bleau, 673K), among other conservative news outlets, running similar analyses. EFTA00149080 To the New York Times (9/22, Fandos, 18.61M), "Romney's dec

n people." Pfizer's COVID Vaccine Trial On Track To Beat Rivals. Bloomberg (9/22, Langreth, 4.73M) reports, "The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals." The firms "plan a first loo

- controlled Senate has enough votes to confirm," with Townhall (9/22, McCarthy, 177K), the Daily Caller (9/22, Rodgers, 716K), and Breitbart (9/22, Bleau, 673K), among other conservative news outlets, running similar analyses. To the New York Times (9/22, Fandos, 18.61M), "Romney's decision capped of